Therapeutic dendritic-cell vaccine for chronic HIV-1 infection
- PMID: 15568033
- DOI: 10.1038/nm1147
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection
Abstract
We present the results of a preliminary investigation of the efficacy of a therapeutic dendritic cell (DC)-based vaccine for HIV-1. We immunized 18 chronically HIV-1-infected and currently untreated individuals showing stable viral loads for at least 6 months with autologous monocyte-derived DCs loaded with autologous aldrithiol-2-inactivated HIV-1. Plasma viral load levels were decreased by 80% (median) over the first 112 d following immunization. Prolonged suppression of viral load of more than 90% was seen in 8 individuals for at least 1 year. The suppression of viral load was positively correlated with HIV-1-specific interleukin-2 or interferon-gamma-expressing CD4(+) T cells and with HIV-1 gag-specific perforin-expressing CD8(+) effector cells, suggesting that a robust virus-specific CD4(+) T-helper type 1 (T(H)1) response is required for inducing and maintaining virus-specific CD8(+) effectors to contain HIV-1 in vivo. The results suggest that inactivated whole virus-pulsed DC vaccines could be a promising strategy for treating people with chronic HIV-1 infection.
Similar articles
-
A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.J Intern Med. 2007 Feb;261(2):123-31. doi: 10.1111/j.1365-2796.2006.01738.x. J Intern Med. 2007. PMID: 17241177
-
CD8+ T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses.Eur J Immunol. 2005 Jan;35(1):159-70. doi: 10.1002/eji.200425744. Eur J Immunol. 2005. PMID: 15580653
-
Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.J Infect Dis. 2005 May 15;191(10):1680-5. doi: 10.1086/429340. Epub 2005 Apr 11. J Infect Dis. 2005. PMID: 15838795
-
Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease.J Antimicrob Chemother. 2006 Apr;57(4):585-8. doi: 10.1093/jac/dkl049. Epub 2006 Feb 27. J Antimicrob Chemother. 2006. PMID: 16504998 Review.
-
What's new in HIV/AIDS. Protective immunity in HIV infection: where do we stand?Infection. 2004 Aug;32(4):250-2. doi: 10.1007/s15010-004-6404-7. Infection. 2004. PMID: 15293085 Review.
Cited by
-
Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses.Viruses. 2022 Sep 14;14(9):2037. doi: 10.3390/v14092037. Viruses. 2022. PMID: 36146843 Free PMC article. Review.
-
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.J Virol. 2012 Sep;86(17):9351-60. doi: 10.1128/JVI.00472-12. Epub 2012 Jun 20. J Virol. 2012. PMID: 22718823 Free PMC article.
-
Dendritic cell dysregulation during HIV-1 infection.Immunol Rev. 2013 Jul;254(1):170-89. doi: 10.1111/imr.12082. Immunol Rev. 2013. PMID: 23772620 Free PMC article. Review.
-
HIV therapeutic vaccines: moving towards a functional cure.Curr Opin Immunol. 2015 Aug;35:1-8. doi: 10.1016/j.coi.2015.05.001. Epub 2015 May 18. Curr Opin Immunol. 2015. PMID: 25996629 Free PMC article. Review.
-
Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model.Immunol Res. 2006;36(1-3):265-74. doi: 10.1385/IR:36:1:265. Immunol Res. 2006. PMID: 17337787 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
